These results expose the accelerated evolution among the key anchoring residues of the RBD–ACE2 interface and raise the following question: how does SARS-2002 RBD reach an ACE2 binding affinity that is comparable to that of COVID-19 but with fewer contact pairs and a smaller interface area? The gene discussed is ACE2; the disease is COVID-19.